A Study to Evaluate the Safety and Efficacy of a Modigraf® Based Immunosuppression Regimen in De Novo Pediatric Allograft Liver and Kidney Transplantation Recipients

Trial Identifier: F506-CL-0406
Sponsor: Astellas Pharma China, Inc.
Start Date: December 2021
Primary Completion Date: March 2024
Study Completion Date: March 2024
Condition: Liver Transplants; Kidney Transplants

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
China Beijing, China
China Changsha, China
China Guangzhou, China
China Shanghai, China
China Tianjin, China
China Wuhan, China
China Zhengzhou, China